Key Chemotherapy Agents in Pediatric Cancer Management

Chemotherapeutic agents remain a cornerstone in the management of pediatric cancers, forming the backbone of treatment regimens for both solid tumors and hematological malignancies. Despite the advent of targeted therapies, traditional cytotoxic drugs continue to demonstrate significant efficacy, particularly when used in combination protocols. This chapter reviews the principal classes of chemotherapeutic agents, including alkylating agents, antimetabolites, topoisomerase inhibitors, anthracyclines, vinca alkaloids, platinum compounds, and antineoplastic enzymes. Each class is discussed in the context of its mechanism of action, pharmacologic properties, clinical indications, and toxicity profiles. Special emphasis is placed on the importance of understanding the tumor cell cycle dynamics and the rationale behind selecting specific agents based on tumor biology. The role of adjuvant, neoadjuvant, and multi-agent chemotherapy in improving survival outcomes is also highlighted. In addition, contemporary approaches to optimizing treatment efficacy while minimizing adverse effects, such as dose-intensity strategies, pharmacokinetic monitoring, and supportive care measures, are discussed. This comprehensive overview provides clinicians with a deeper understanding of how conventional chemotherapeutic agents are integrated into modern pediatric oncology practice, ensuring effective, evidence-based management of young cancer patients.